Peter Loftus
@loftus.bsky.social
Reporter covering drug companies, medical-device companies for The Wall Street Journal. Author of The Messenger: Moderna, the Vaccine, and the Business Gamble That Changed the World
In other obesity drug news, Amgen shares are down more than 10% today because investors were underwhelmed by magnitude of weight loss, tolerability data from new study of its experimental med: www.wsj.com/health/pharm...
Amgen Obesity Drug Cut Weight In Closely Watched Study
Study subjects taking the company’s MariTide lost about 20% of their weight in the 52-week trial.
www.wsj.com
November 26, 2024 at 4:54 PM
In other obesity drug news, Amgen shares are down more than 10% today because investors were underwhelmed by magnitude of weight loss, tolerability data from new study of its experimental med: www.wsj.com/health/pharm...